Skip to main content
Article thumbnail
Location of Repository

The HSP90 Inhibitor NVP-AUY922 Radiosensitizes by Abrogation of Homologous Recombination Resulting in Mitotic Entry with Unresolved DNA Damage

By Shane Zaidi, Martin McLaughlin, Shreerang A. Bhide, Suzanne A. Eccles, Paul Workman, Christopher M. Nutting, Robert A. Huddart and Kevin J. Harrington
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2010). (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
  2. (2008). 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
  3. (2007). A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children’s Oncology Group study.
  4. (2011). A Phase I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced, solid tumors.
  5. (2006). A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.
  6. (2008). A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
  7. (2010). A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Investigational new drugs.
  8. (2010). BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
  9. (2004). Cell death by mitotic catastrophe: a molecular definition.
  10. (2006). Chaperoning checkpoint kinase 1 (CHK1), an Hsp90 client, with purified chaperones.
  11. (2007). Chromosome breakage after G2 checkpoint release.
  12. (2006). Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI504), an anti-cancer agent directed against
  13. (2007). Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
  14. (2008). Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
  15. (2003). Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.
  16. (2009). Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.
  17. (2004). Enhanced tumor cell radiosensitivity and abrogation
  18. (2003). Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
  19. (2008). Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells.
  20. (2003). Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation.
  21. (2010). Guidelines for the welfare and use of animals in cancer research.
  22. (2005). Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis.
  23. (2011). Hsp90 inhibitor mediated disruption of chaperone association of ATR with Hsp90 sensitizes cancer cells to DNA damage. Mol Cancer Ther.
  24. (2008). HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair.
  25. (2007). Hsp90 regulates the Fanconi anemia DNA damage response pathway.
  26. (2006). Induction of the 72-kilodalton heat shock protein and protection from ultraviolet B-induced cell death in human keratinocytes by repetitive exposure to heat shock or 15-deoxy-delta(12,14)-prostaglandin J2.
  27. (2006). Inhibition of homologous recombination repair in irradiated tumor cells pretreated with
  28. (2010). Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.
  29. (2004). Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy.
  30. (2010). Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
  31. (2010). nuclear medicine : official publication,
  32. (2008). NVPAUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
  33. (2008). NVPAUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
  34. (2005). Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
  35. (2005). Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.
  36. (2010). Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800.
  37. (2005). Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin.
  38. (2008). Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino17-demethoxygeldanamycin.
  39. (2003). sensitizes tumor cells to replication stress.
  40. (2008). Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVPAUY922 in multiple myeloma.
  41. (2006). Structure and mechanism of the Hsp90 molecular chaperone machinery.
  42. (2007). Synergism between etoposide and 17-AAG in leukemia cells: critical roles for
  43. (2010). Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.
  44. (2010). Targeting the dynamic HSP90 complex in cancer.
  45. (2009). The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe.
  46. (2008). The Hsp90 molecular chaperone: an open and shut case for treatment.
  47. (2007). The impact of a negligent G2/M checkpoint on genomic instability and cancer induction.
  48. Tofilon PJ (2005) ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.
  49. Tofilon PJ (2007) Inhibition of Hsp90: a multitarget approach to radiosensitization.
  50. (2008). Triggering senescence programs suppresses Chk1 kinase and sensitizes cells to genotoxic stresses.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.